Transforming Neurohealth

Neuronetics, Inc. is a commercial-stage medical device company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.

Neuronetics’ NeuroStar^® Advanced Therapy System, is the leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder and is backed by the largest clinical data set of any TMS system.^{6, 7, 8, 10, 11, 20}

Our Vision:
Neurohealth achieved
for people everywhere

We designed NeuroStar as a non-invasive therapeutic alternative to treat patients who suffer from major depressive disorder and to address many of the key limitations of existing treatment options. NeuroStar therapy provides our psychiatrist customers and their patients with several benefits, including^{11, 20}

Clinically demonstrated response and remission with durable results
A demonstrated safety profile with limited treatment-emergent side effects
High patient adherence

Additionally, our therapy was designed to provide a precise and reproducible office-based therapy that is also efficient and convenient.

NEURONETICS TEAM

Dedicated and experienced management team
and board that puts patients and customers first.

Meet our

CAREERS

Transforming lives
starts with you

We’re looking for the best and brightest to join
us in realizing neurohealth achieved for people
everywhere.

Neuronetics Timeline

1998:

Invention

Chip Epstein and Kent Davey invented and patented the first iron core coil
Business incubation began at the Innovation Factory

2003:

Neuronetics is Founded

The iron core technology is licensed from Emory University
Clinical Trials begin US, Canada and Australia

2004:

Designs Begin on the NeuroStar System

2006:

Filed 501K with FDA

2008:

FDA Clearance Awarded

Neuronetics claims many design awards
The first NeuroStar system is sold
Largest randomized controlled trial for TMS in depression is published

2009:

First Insurance Coverage

2010:

American Psychiatric Association Adds TMS to Practices Guidelines for Major Depressive Disorder

NIMH sponsored randomized controlled trial published
American Museum of Natural History in NYC features NeuroStar in a special exhibition of the brain

2011:

Technology Pioneer Award

Time magazine honors Neuronetics with a Global Business Award
World Economic Forum presents a Technology Pioneer Award to Neuronetics

2012:

NeuroStar Products Receive an International CE Mark

Phoenix Award - Most Promising New Product

2013:

Celebrating 10 Years

510K submission for label expansion

2014:

Long Term Durability Study Completed

NeuroStar 360 TMS Education Conference Series

2015:

Adolescent Study Begins

Chris Thatcher begins first full year as president and CEO

2016:

1 Million Treatments

Most major insurers cover TMS
Medicare and Tricare covered coast-to-coast

2017:

NeuroStar Brand Transformation

Neuronetics receives FDA clearance for 19 min DASH protocol
TMS TrakStar Cloud developed for a premium patient management experience
NeuroStar Patient Outcomes Registry is launched
NeuroStar Advanced Therapy Approved to Treat Depression in Japan

2018:

Neuronetics Announces IPO

First national TV campaign in the industry airs
NeuroStar Patient Advisory Council is created
Two Million Treatments

NeuroStar - Making Headlines

See what people are saying about us.

Our Mission: Renewing Lives by Transforming Neurohealth

Transforming Neurohealth

Our Vision: Neurohealth achieved for people everywhere

Dedicated and experienced management team and board that puts patients and customers first.

Transforming lives starts with you